{"url_path":"/sec/aldx/8-k/2026-07-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1341235/0001193125-26-304880-index.html","accession_number":"0001193125-26-304880","cik":"0001341235","ticker":"ALDX","issuer_name":"Aldeyra Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1341235/0001193125-26-304880-index.html","primary_entity_key":"0001341235","primary_entity_name":"Aldeyra Therapeutics, Inc."},"word_count":157,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nOn July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Application (NDA) of reproxalap for the treatment of dry eye disease. On July 15, 2026, Aldeyra requested a clarification of the Minutes from the FDA. In addition, Aldeyra intends to request a Type D meeting with the FDA to discuss potential resubmission of the NDA. The Type D meeting is expected to be held by the end of the third quarter of 2026.\n\n \n\n \n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nALDEYRA THERAPEUTICS, INC.\n\n \n\n \n\nBy:\n\n/s/ Todd C. Brady\n\nName:\n\nTodd C. Brady M.D., Ph.D.\n\nTitle:\n\nChief Executive Officer\n\nDated July 15, 2026"}